WO2001030372A2 - Zubereitungen pharmazeutischer wirkstoffe - Google Patents
Zubereitungen pharmazeutischer wirkstoffe Download PDFInfo
- Publication number
- WO2001030372A2 WO2001030372A2 PCT/EP2000/010205 EP0010205W WO0130372A2 WO 2001030372 A2 WO2001030372 A2 WO 2001030372A2 EP 0010205 W EP0010205 W EP 0010205W WO 0130372 A2 WO0130372 A2 WO 0130372A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active ingredient
- component
- dosage form
- solid dosage
- form according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Definitions
- a whole series of highly effective pharmaceutical active substances 15 causes great problems with regard to the bioavailability of the dosage forms, in particular if, in the context of long-term therapy, uniform blood plasma concentrations are desired, but excessively high blood plasma levels have to be avoided because of the strong side effects. This applies, for example, to many 20 immunosuppressants, HIV therapeutics or CNS-active substances.
- the dosage form according to the invention is suitable in principle for all poorly water-soluble and poorly bioavailable active ingredients, but in particular for cyclosporin.
- Cyclosporin A has a melting point of 148 to 151 ° C. and is used as a colorless, crystalline substance.
- a molecularly disperse solution of the active ingredient in the selected solvent is dissolved at temperatures in the range from preferably 20 to 150 ° C., within a period of less than 120 seconds, optionally with an excess pressure of up to 100 bar, preferably 30 bar.
- the mixing process can be carried out batchwise or, preferably, continuously.
- the active ingredient is precipitated in the form of solid, X-ray amorphous particles.
- the colloidal suspension obtained in this way can then be converted into a dry powder in a manner known per se, for example by spray drying, freeze drying or drying in a fluidized bed.
- processing is generally carried out at temperatures of 40 to 260 ° C., preferably 50 to 200 ° C.
- the second preparation forms can contain, for example, thermoplastically processable water-soluble or water-swellable polymers as suitable matrix formers.
- Water-soluble means that at 25 ° C at least 1 g of the polymer dissolve in 10 ml of water.
- Water-swellable means that the water absorption at 25 ° C. and 75% relative air humidity is more than 1% by weight without the polymer dissolving.
- Sugar alcohols such as erythritol, isomalt, mannitol, sorbitol, xylitol or mixtures of such sugar alcohols are also suitable as matrix formers.
- the matrix can also contain pharmaceutically acceptable auxiliaries such as fillers, lubricants, mold release agents, flow regulators, plasticizers, colorants, flavorings and / or stabilizers in the amounts customary for this.
- auxiliaries such as fillers, lubricants, mold release agents, flow regulators, plasticizers, colorants, flavorings and / or stabilizers in the amounts customary for this.
- the active ingredient in this preparation form is in the form of a pure crystalline substance without further auxiliaries.
- the particles have average diameters in the range from 0.05 to 200 ⁇ m, preferably 0.1 to 50 ⁇ m.
- the crystalline particles can be obtained from crystalline raw materials by grinding processes known per se. Suitable grinding processes are, for example, dry or wet grinding. Suitable devices are, for example, ball mills, pin mills or air jet mills.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001532789A JP2004500343A (ja) | 1999-10-26 | 2000-10-17 | 医薬製剤 |
EP00972786A EP1223960A2 (de) | 1999-10-26 | 2000-10-17 | Zubereitungen pharmazeutischer wirkstoffe |
CA002388614A CA2388614A1 (en) | 1999-10-26 | 2000-10-17 | Pharmaceutical agent preparations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19951617A DE19951617A1 (de) | 1999-10-26 | 1999-10-26 | Zubereitungen pharmazeutische Wirkstoffe |
DE19951617.0 | 1999-10-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001030372A2 true WO2001030372A2 (de) | 2001-05-03 |
WO2001030372A3 WO2001030372A3 (de) | 2001-11-01 |
Family
ID=7926968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/010205 WO2001030372A2 (de) | 1999-10-26 | 2000-10-17 | Zubereitungen pharmazeutischer wirkstoffe |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1223960A2 (de) |
JP (1) | JP2004500343A (de) |
CN (1) | CN1384753A (de) |
CA (1) | CA2388614A1 (de) |
DE (1) | DE19951617A1 (de) |
PL (1) | PL354991A1 (de) |
WO (1) | WO2001030372A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465016B2 (en) * | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR033711A1 (es) * | 2001-05-09 | 2004-01-07 | Novartis Ag | Composiciones farmaceuticas |
DE102005026755A1 (de) * | 2005-06-09 | 2006-12-14 | Basf Ag | Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010767A1 (de) * | 1991-12-05 | 1993-06-10 | Alfatec-Pharma Gmbh | Perorale applikationsform für peptidarzneistoffe, insbesondere insulin |
WO1995016438A1 (en) * | 1993-12-13 | 1995-06-22 | Cortecs Limited | Biphasic capsule formulation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0816053B2 (ja) * | 1986-12-04 | 1996-02-21 | 大正製薬株式会社 | 貼付剤の製造方法 |
JPH0436237A (ja) * | 1990-06-01 | 1992-02-06 | Taiho Yakuhin Kogyo Kk | 抗腫瘍性複合製剤 |
JP4189044B2 (ja) * | 1997-07-01 | 2008-12-03 | 大正製薬株式会社 | マルチプルユニットタイプ徐放性錠剤 |
-
1999
- 1999-10-26 DE DE19951617A patent/DE19951617A1/de not_active Withdrawn
-
2000
- 2000-10-17 WO PCT/EP2000/010205 patent/WO2001030372A2/de not_active Application Discontinuation
- 2000-10-17 JP JP2001532789A patent/JP2004500343A/ja not_active Withdrawn
- 2000-10-17 CA CA002388614A patent/CA2388614A1/en not_active Abandoned
- 2000-10-17 EP EP00972786A patent/EP1223960A2/de not_active Withdrawn
- 2000-10-17 PL PL00354991A patent/PL354991A1/xx unknown
- 2000-10-17 CN CN00814940A patent/CN1384753A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010767A1 (de) * | 1991-12-05 | 1993-06-10 | Alfatec-Pharma Gmbh | Perorale applikationsform für peptidarzneistoffe, insbesondere insulin |
WO1995016438A1 (en) * | 1993-12-13 | 1995-06-22 | Cortecs Limited | Biphasic capsule formulation |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Section Ch, Week 198829 Derwent Publications Ltd., London, GB; Class B07, AN 1988-202954 XP002165958 & JP 63 141923 A (TAISHO PHARM CO LTD), 14. Juni 1988 (1988-06-14) * |
DATABASE WPI Section Ch, Week 199212 Derwent Publications Ltd., London, GB; Class B03, AN 1992-092932 XP002165957 & JP 04 036237 A (TAIHO PHARM CO LTD), 6. Februar 1992 (1992-02-06) * |
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 04, 30. April 1999 (1999-04-30) & JP 11 021233 A (TAISHO PHARMACEUT CO LTD), 26. Januar 1999 (1999-01-26) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465016B2 (en) * | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
Also Published As
Publication number | Publication date |
---|---|
WO2001030372A3 (de) | 2001-11-01 |
JP2004500343A (ja) | 2004-01-08 |
EP1223960A2 (de) | 2002-07-24 |
PL354991A1 (en) | 2004-03-22 |
DE19951617A1 (de) | 2001-05-03 |
CA2388614A1 (en) | 2001-05-03 |
CN1384753A (zh) | 2002-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1162953B1 (de) | Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen | |
EP1073426B1 (de) | Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung | |
DE69916733T3 (de) | Stabile Komplexe schwer löslicher Substanzen | |
DE3013839C2 (de) | ||
WO1993010768A1 (de) | Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung | |
DE10046541A1 (de) | Mechanisch stabile darreichungsformen, enthaltend Ubichinone | |
EP0615442B1 (de) | Sol-gesteuerte thermokolloidmatrix auf gelatine basis für perorale retardformen | |
EP0596203A1 (de) | Wirkstoffe und wasserlösliche Polymeren enthaltende Zubereitungen in Form fester Teilchen | |
WO2001000175A1 (de) | Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen | |
EP2595607A2 (de) | Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer | |
EP0697867B1 (de) | Zubereitungen in form fester lösungen | |
WO2009056266A2 (de) | Candesartancilexetil | |
DE69910188T2 (de) | Arzneiformen enthaltend carvedilol | |
DE4140184C2 (de) | Akutform für ein Flurbiprofen enthaltendes Arzneimittel | |
EP1142571B1 (de) | Verfahren zur Herstellung von festen Kreatin-Dosierungsformen und dadurch erhältliche Dosierungsformen | |
WO2001030372A2 (de) | Zubereitungen pharmazeutischer wirkstoffe | |
EP1077676A2 (de) | Cyclosporin-zubereitungen | |
DE102011053068A1 (de) | Darreichungsform mit stabilisierten Wirkstoffpartikeln | |
DE19930454A1 (de) | Feste Paroxetin enthaltende Zubereitungen | |
WO1993010771A1 (de) | Ein flurbiprofen enthaltendes retard-arzneimittel und seine verwendung | |
DE102019119163A1 (de) | Nanostrukturierte Ibuprofen-Zusammensetzungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
EP1682086A2 (de) | Arzneimittelformulierung, enthaltend einen ltb4-antagonisten, sowie verfahren zu deren herstellung und deren verwendung | |
DE202020005452U1 (de) | Zusammensetzung, enthaltend natürliche lipophile Verbindungen | |
EP0615446B1 (de) | Ein dihydropyridinderivat in nanosolform enthaltendes retard-arzneimittel und seine herstellung | |
DE19816036A1 (de) | Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA CN JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA CN JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000972786 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10110533 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2388614 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 532789 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008149402 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2000972786 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000972786 Country of ref document: EP |